ALMRNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Alamar Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$26.30+1.02 (+4.03%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $29.40M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 8, 2026 | Before market open | $26.00M | – | – |
Company guidance
Outlook given with results on Aug 10, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| growth | full year 2026 | 59% growth | New |
| revenue | full year 2026 | $116.00M to $120.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Alamar Biosciences filed with the SEC
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Alamar Biosciences Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K